| 0.356 0.023 (6.78%) | 11-09 10:52 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.49 | 1-year : | 0.57 |
| Resists | First : | 0.42 | Second : | 0.49 |
| Pivot price | 0.37  |
|||
| Supports | First : | 0.31 | Second : | 0.26 |
| MAs | MA(5) : | 0.34 |
MA(20) : | 0.38 |
| MA(100) : | 0.74 |
MA(250) : | 1.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.8 |
D(3) : | 10.5 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 2.39 | Low : | 0.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BBLG ] has closed below upper band by 39.9%. Bollinger Bands are 53.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 48 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.36 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.33 - 0.33 | 0.33 - 0.34 |
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Fri, 30 Oct 2026
Bone Biologics Corporation (BBLG) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Tue, 27 Oct 2026
Cash Runways: Acumen Pharmaceuticals (NASDAQ:ABOS) and Bone Biologics (NASDAQ:BBLG) Funding Plans - kalkine.ca
Tue, 13 Oct 2026
Nasdaq files to remove Bone Biologics (Nasdaq: BBLG) warrants from listing and/or registration. - Stock Titan
Wed, 16 Sep 2026
Bone Biologics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Wed, 12 Aug 2026
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1 - Yahoo Finance
Tue, 07 Jul 2026
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 36 (K) |
| EPS | -1.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.5 % |
| Return on Equity (ttm) | -47.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.39 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|